Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2009

View Archived Issues

Odanacatib progressively increases bone mineral density in postmenopausal women over 2 years

Quetiapine improves PTSD measures in randomized study

Novel oxazolidinone shows preclinical antibacterial activity and clinical safety in healthy subjects

Sanofi-aventis presents novel histamine H3 receptor modulators for sleep disorders

Allergan claims prostanoid EP2 receptor agonists for the treatment of glaucoma

Genzyme reviews developments of first quarter

Glomerular filtration rate improved with pirfenidone in diabetic nephropathy patients

Denosumab: Snapshots of recent clinical and preclinical studies

Merck KGaA prepares and tests novel 11beta-HSD1 inhibitors

Abbott presents 5-HT6 receptor ligands for the treatment of cognitive dysfunctions

Bristol-Myers Squibb discloses androgen receptor antagonists for the treatment of cancer

Acure initiates phase I clinical trial of novel compound for RA and pain relief

COMP issues positive opinion for orphan drug designation for Camurus' CAM-2029

CTx progresses preclinical cancer drug against FAK enzyme into lead optimization phase

Amgen exercises option to licence Cytokinetics' cardiac contractility program

Novel dual muscarinic antagonist and beta2-adrenoceptor agonist developed for bronchodilator therapy

Dr. Reddy's receives approval for INDs and reorganizes drug discovery operations

Muscarinic receptor antagonist TD-4208 shows preclinical potential for the treatment of COPD

Novel histamine H3 receptor inverse agonist developed by Roche for the treatment of obesity

FDA accepts Allos' pralatrexate NDA for filing and grants priority review

Long-term fermagate treatment holds down phosphate levels in hemodialysis patients

FDA approves Adcirca tablets for pulmonary arterial hypertension

FDA notifies Hemispherx of possible delay in FDA action on Ampligen

Health Canada approves GSK's Tykerb in combination with Xeloda for breast cancer

Bristol-Myers Squibb submits CTA in Sweden to initiate phase I studies on drug for CNS diseases

European Commission grants marketing authorization to HRA Pharma's ellaOne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...